167 related articles for article (PubMed ID: 8986036)
1. Lack of correlation between prostate-specific antigen density and prostatic shrinkage in response to finasteride therapy.
Kirschenbaum A; Pacheco E; Schuval BJ; Levine AC
World J Urol; 1996; 14(6):360-2. PubMed ID: 8986036
[TBL] [Abstract][Full Text] [Related]
2. Effects of finasteride on prostate volume and prostate-specific antigen.
Chiu KY; Yong CR
J Chin Med Assoc; 2004 Nov; 67(11):571-4. PubMed ID: 15720071
[TBL] [Abstract][Full Text] [Related]
3. The effect of finasteride on prostate specific antigen: review of available data.
Guess HA; Gormley GJ; Stoner E; Oesterling JE
J Urol; 1996 Jan; 155(1):3-9. PubMed ID: 7490873
[TBL] [Abstract][Full Text] [Related]
4. Comparison of percent free prostate-specific antigen levels in men with benign prostatic hyperplasia treated with finasteride, terazosin, or watchful waiting.
Keetch DW; Andriole GL; Ratliff TL; Catalona WJ
Urology; 1997 Dec; 50(6):901-5. PubMed ID: 9426721
[TBL] [Abstract][Full Text] [Related]
5. Serum prostate-specific antigen concentration is a powerful predictor of acute urinary retention and need for surgery in men with clinical benign prostatic hyperplasia. PLESS Study Group.
Roehrborn CG; McConnell JD; Lieber M; Kaplan S; Geller J; Malek GH; Castellanos R; Coffield S; Saltzman B; Resnick M; Cook TJ; Waldstreicher J
Urology; 1999 Mar; 53(3):473-80. PubMed ID: 10096369
[TBL] [Abstract][Full Text] [Related]
6. Prostate tissue composition and response to finasteride in men with symptomatic benign prostatic hyperplasia.
Marks LS; Partin AW; Gormley GJ; Dorey FJ; Shery ED; Garris JB; Subong EN; Stoner E; deKernion JB
J Urol; 1997 Jun; 157(6):2171-8. PubMed ID: 9146609
[TBL] [Abstract][Full Text] [Related]
7. [Specific antigen prostatic changes during treatment with finasteride or dutasteride for benign prostatic hyperplasia].
Arena F
Minerva Urol Nefrol; 2013 Sep; 65(3):211-6. PubMed ID: 23872632
[TBL] [Abstract][Full Text] [Related]
8. Influence of finasteride on free and total serum prostate specific antigen levels in men with benign prostatic hyperplasia.
Pannek J; Marks LS; Pearson JD; Rittenhouse HG; Chan DW; Shery ED; Gormley GJ; Subong EN; Kelley CA; Stoner E; Partin AW
J Urol; 1998 Feb; 159(2):449-53. PubMed ID: 9649261
[TBL] [Abstract][Full Text] [Related]
9. [PSA values before and after finasteride treatment in patients with benign prostatic hypertrophy].
Trinchieri A; Dell'Orto P
Arch Ital Urol Androl; 1995 Feb; 67(1):33-5. PubMed ID: 7538385
[TBL] [Abstract][Full Text] [Related]
10. Effect of finasteride on free and total serum prostate-specific antigen in men with benign prostatic hyperplasia.
Matzkin H; Barak M; Braf Z
Br J Urol; 1996 Sep; 78(3):405-8. PubMed ID: 8881951
[TBL] [Abstract][Full Text] [Related]
11. Early diagnosis of prostate cancer in finasteride treated BPH patients.
Tarle M; Kraus O; Trnski D; Reljic A; Ruzic B; Katusic J; Spajic B; Kusic Z
Anticancer Res; 2003; 23(1B):693-6. PubMed ID: 12680169
[TBL] [Abstract][Full Text] [Related]
12. Changes in molecular forms of prostate-specific antigen during treatment with finasteride.
España F; Martínez M; Royo M; Estellés A; Alapont JM; Navarro S; Aznar J; Jiménez-Cruz JF
BJU Int; 2002 Nov; 90(7):672-7. PubMed ID: 12410745
[TBL] [Abstract][Full Text] [Related]
13. Biologic variability of prostate-specific antigen and its usefulness as a marker for prostate cancer: effects of finasteride. The Finasteride PSA Study Group.
Oesterling JE; Roy J; Agha A; Shown T; Krarup T; Johansen T; Lagerkvist M; Gormley G; Bach M; Waldstreicher J
Urology; 1997 Jul; 50(1):13-8. PubMed ID: 9218012
[TBL] [Abstract][Full Text] [Related]
14. Effect of finasteride on serum PSA concentration in men with benign prostatic hyperplasia. Results from the North American phase III clinical trial.
Guess HA; Heyse JF; Gormley GJ; Stoner E; Oesterling JE
Urol Clin North Am; 1993 Nov; 20(4):627-36. PubMed ID: 7505970
[TBL] [Abstract][Full Text] [Related]
15. Prostate volume and serum prostate-specific antigen as predictors of acute urinary retention. Combined experience from three large multinational placebo-controlled trials.
Marberger MJ; Andersen JT; Nickel JC; Malice MP; Gabriel M; Pappas F; Meehan A; Stoner E; Waldstreicher J
Eur Urol; 2000 Nov; 38(5):563-8. PubMed ID: 11096237
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of men on finasteride.
Gormley GJ
Semin Urol Oncol; 1996 Aug; 14(3):139-44. PubMed ID: 8865475
[TBL] [Abstract][Full Text] [Related]
17. Serum prostate-specific antigen and prostate volume predict long-term changes in symptoms and flow rate: results of a four-year, randomized trial comparing finasteride versus placebo. PLESS Study Group.
Roehrborn CG; Boyle P; Bergner D; Gray T; Gittelman M; Shown T; Melman A; Bracken RB; deVere White R; Taylor A; Wang D; Waldstreicher J
Urology; 1999 Oct; 54(4):662-9. PubMed ID: 10510925
[TBL] [Abstract][Full Text] [Related]
18. Differential effect of finasteride on the tissue androgen concentrations in benign prostatic hyperplasia.
Habib FK; Ross M; Tate R; Chisholm GD
Clin Endocrinol (Oxf); 1997 Feb; 46(2):137-44. PubMed ID: 9135694
[TBL] [Abstract][Full Text] [Related]
19. Effect of finasteride on prostate-specific antigen density.
Gormley GJ; Ng J; Cook T; Stoner E; Guess H; Walsh P
Urology; 1994 Jan; 43(1):53-8; discussion 58-9. PubMed ID: 7506854
[TBL] [Abstract][Full Text] [Related]
20. 5alpha-reductase inhibitors: what role should they play?
Kaplan SA
Urology; 2001 Dec; 58(6 Suppl 1):65-70; discussion 70. PubMed ID: 11750255
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
